HONOURING A LEGACY
THROUGH INNOVATION

When John Hunkin, pictured with his wife Susan Crocker, suddenly passed away in early 2025, gifts were made in memory of his passion to advance innovation in health care.


HONOURING A LEGACY THROUGH INNOVATION

When John Hunkin, pictured with his wife Susan Crocker, suddenly passed away in early 2025, gifts were made in memory of his passion to advance innovation in health care.

$73,555

RECEIVED IN MEMORY TO HELP FUND INNOVATION CATALYST GRANTS

John had a beautiful way of encouraging others to dream big and imagine what’s possible. It was his vision that helped create the QEII Foundation’s Innovation Catalyst Fund in 2023. This Fund provides grants to healthcare teams to fast-track innovative concepts and to implement solutions that will improve patients’ lives.

The community was deeply saddened by John’s passing in January 2025. To honour his incredible legacy, many gifts were made to the Innovation Catalyst Fund in his memory, including a special gift from CIBC as John had a long career in the financial industry.

John’s desire was always to inspire others to believe in the power of ideas. Since establishing the Innovation Catalyst Fund with a generous $1-million gift, John’s visionary thinking has ensured many grants have been awarded and are already making a difference for patients. Gifts made in his memory will fuel even more projects to transform care at and through the QEII.

The QEII has the size, scale, and talent to make a huge impact on medical innovation. There is already a vast amount of leading research and innovation happening here but there is still great opportunity to introduce more.

— John Hunkin, during an interview in 2023

WHAT DONORS WILL MAKE POSSIBLE:

Supporting medical discoveries for new products, therapies or treatments to improve patient care..

Helping to solve healthcare challenges that increase efficiencies, reduce health system costs and improve patient equity.

Accelerating system-wide transformation by investing in people with innovative solutions on refining systems, launching field studies and trials, and building prototypes.